Chapter/Section Purchase

1 Study Coverage
1.1 Rare Neurodegenerative Disease Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Rare Neurodegenerative Disease Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Rare Neurodegenerative Disease Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Amyotrophic Lateral Sclerosis (ALS)
1.3.3 Attention Deficit Hyperactivity Disorder (ADHD)
1.3.4 Alzheimer?s Disease
1.3.5 Parkinson?s Disease
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Rare Neurodegenerative Disease Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Rare Neurodegenerative Disease Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Rare Neurodegenerative Disease Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Rare Neurodegenerative Disease Treatment Sales by Region
2.4.1 Global Rare Neurodegenerative Disease Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Rare Neurodegenerative Disease Treatment by Region (2023-2028)
2.5 Global Rare Neurodegenerative Disease Treatment Revenue by Region
2.5.1 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2017-2022)
2.5.2 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Rare Neurodegenerative Disease Treatment Sales by Manufacturers
3.1.1 Global Top Rare Neurodegenerative Disease Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Rare Neurodegenerative Disease Treatment in 2021
3.2 Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturers
3.2.1 Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Rare Neurodegenerative Disease Treatment Revenue in 2021
3.3 Global Rare Neurodegenerative Disease Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Rare Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Rare Neurodegenerative Disease Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Rare Neurodegenerative Disease Treatment Sales by Type
4.1.1 Global Rare Neurodegenerative Disease Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Rare Neurodegenerative Disease Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2017-2028)
4.2 Global Rare Neurodegenerative Disease Treatment Revenue by Type
4.2.1 Global Rare Neurodegenerative Disease Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Rare Neurodegenerative Disease Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Rare Neurodegenerative Disease Treatment Price by Type
4.3.1 Global Rare Neurodegenerative Disease Treatment Price by Type (2017-2022)
4.3.2 Global Rare Neurodegenerative Disease Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Rare Neurodegenerative Disease Treatment Sales by Application
5.1.1 Global Rare Neurodegenerative Disease Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Rare Neurodegenerative Disease Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2017-2028)
5.2 Global Rare Neurodegenerative Disease Treatment Revenue by Application
5.2.1 Global Rare Neurodegenerative Disease Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Rare Neurodegenerative Disease Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Rare Neurodegenerative Disease Treatment Price by Application
5.3.1 Global Rare Neurodegenerative Disease Treatment Price by Application (2017-2022)
5.3.2 Global Rare Neurodegenerative Disease Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Rare Neurodegenerative Disease Treatment Market Size by Type
6.1.1 North America Rare Neurodegenerative Disease Treatment Sales by Type (2017-2028)
6.1.2 North America Rare Neurodegenerative Disease Treatment Revenue by Type (2017-2028)
6.2 North America Rare Neurodegenerative Disease Treatment Market Size by Application
6.2.1 North America Rare Neurodegenerative Disease Treatment Sales by Application (2017-2028)
6.2.2 North America Rare Neurodegenerative Disease Treatment Revenue by Application (2017-2028)
6.3 North America Rare Neurodegenerative Disease Treatment Market Size by Country
6.3.1 North America Rare Neurodegenerative Disease Treatment Sales by Country (2017-2028)
6.3.2 North America Rare Neurodegenerative Disease Treatment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Rare Neurodegenerative Disease Treatment Market Size by Type
7.1.1 Europe Rare Neurodegenerative Disease Treatment Sales by Type (2017-2028)
7.1.2 Europe Rare Neurodegenerative Disease Treatment Revenue by Type (2017-2028)
7.2 Europe Rare Neurodegenerative Disease Treatment Market Size by Application
7.2.1 Europe Rare Neurodegenerative Disease Treatment Sales by Application (2017-2028)
7.2.2 Europe Rare Neurodegenerative Disease Treatment Revenue by Application (2017-2028)
7.3 Europe Rare Neurodegenerative Disease Treatment Market Size by Country
7.3.1 Europe Rare Neurodegenerative Disease Treatment Sales by Country (2017-2028)
7.3.2 Europe Rare Neurodegenerative Disease Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Rare Neurodegenerative Disease Treatment Market Size by Type
8.1.1 Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Rare Neurodegenerative Disease Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Rare Neurodegenerative Disease Treatment Market Size by Application
8.2.1 Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Rare Neurodegenerative Disease Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Rare Neurodegenerative Disease Treatment Market Size by Region
8.3.1 Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Rare Neurodegenerative Disease Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Rare Neurodegenerative Disease Treatment Market Size by Type
9.1.1 Latin America Rare Neurodegenerative Disease Treatment Sales by Type (2017-2028)
9.1.2 Latin America Rare Neurodegenerative Disease Treatment Revenue by Type (2017-2028)
9.2 Latin America Rare Neurodegenerative Disease Treatment Market Size by Application
9.2.1 Latin America Rare Neurodegenerative Disease Treatment Sales by Application (2017-2028)
9.2.2 Latin America Rare Neurodegenerative Disease Treatment Revenue by Application (2017-2028)
9.3 Latin America Rare Neurodegenerative Disease Treatment Market Size by Country
9.3.1 Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2017-2028)
9.3.2 Latin America Rare Neurodegenerative Disease Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Market Size by Type
10.1.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Market Size by Application
10.2.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Rare Neurodegenerative Disease Treatment Market Size by Country
10.3.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Overview
11.1.3 Bayer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bayer Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Recent Developments
11.3 Hoffmann-La Roche
11.3.1 Hoffmann-La Roche Corporation Information
11.3.2 Hoffmann-La Roche Overview
11.3.3 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Hoffmann-La Roche Recent Developments
11.4 Allergan
11.4.1 Allergan Corporation Information
11.4.2 Allergan Overview
11.4.3 Allergan Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Allergan Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Allergan Recent Developments
11.5 Merck KGaA
11.5.1 Merck KGaA Corporation Information
11.5.2 Merck KGaA Overview
11.5.3 Merck KGaA Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Merck KGaA Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merck KGaA Recent Developments
11.6 Johnson and Johnson
11.6.1 Johnson and Johnson Corporation Information
11.6.2 Johnson and Johnson Overview
11.6.3 Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Johnson and Johnson Recent Developments
11.7 Pfizer
11.7.1 Pfizer Corporation Information
11.7.2 Pfizer Overview
11.7.3 Pfizer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Pfizer Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Pfizer Recent Developments
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Overview
11.8.3 Novartis Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Novartis Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis Recent Developments
11.9 Sanofi
11.9.1 Sanofi Corporation Information
11.9.2 Sanofi Overview
11.9.3 Sanofi Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Sanofi Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sanofi Recent Developments
11.10 Teva Pharmaceuticals
11.10.1 Teva Pharmaceuticals Corporation Information
11.10.2 Teva Pharmaceuticals Overview
11.10.3 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Teva Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Rare Neurodegenerative Disease Treatment Industry Chain Analysis
12.2 Rare Neurodegenerative Disease Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Rare Neurodegenerative Disease Treatment Production Mode & Process
12.4 Rare Neurodegenerative Disease Treatment Sales and Marketing
12.4.1 Rare Neurodegenerative Disease Treatment Sales Channels
12.4.2 Rare Neurodegenerative Disease Treatment Distributors
12.5 Rare Neurodegenerative Disease Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Rare Neurodegenerative Disease Treatment Industry Trends
13.2 Rare Neurodegenerative Disease Treatment Market Drivers
13.3 Rare Neurodegenerative Disease Treatment Market Challenges
13.4 Rare Neurodegenerative Disease Treatment Market Restraints
14 Key Findings in The Global Rare Neurodegenerative Disease Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer